Founding Partner & Managing Director, Brandon Capital
Stories naming Dr Stephen Thompson. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Novartis is acquiring London biotech Myricx Bio for US$1.1 billion upfront plus milestone payments, handing Melbourne venture firm Brandon Capital a record return on the startup it seeded in 2019.
Also Forbes Australia
Perth medtech OncoRes Medical announced $12.5 million: a $9.5 million Series A2 co-led by Brandon Capital and Australian Unity, plus a $3 million government grant, and hired a new R&D vice president.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Startup News (WA)
UK biotech Myricx Pharma launched with a £4.5 million seed round from Sofinnova Partners and Brandon Capital to advance its NMT-inhibitor cancer drug discovery work.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio
Australian genomics spin-out Longas has come out of stealth with technology that extends DNA sequencing read length, backed by the MRCF and its founders, and appoints Solexa's founding chief executive Nick McCooke as CEO.
A university spin-out launches with venture and founder backing, introducing a technology that extends DNA sequencing read lengths, and appointing a new chief executive to commercialise it.